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Abstract We have used subtractive hybridization to isolate 
cDNAs overexpressed in SK-PC-l pancreas cancer cells. Forty- 
five independent clones corresponding to 11 genes were identified. 
Their expression in cultured pancreas cancer cells, normal 
pancreas tissue, and normal exocrine pancreas cultures was 
examined by Northern blotting. cDNA clones can be grouped 
into two broad categories: (1) those corresponding to genes 
expressed at high levels both in tumor cell lines and in primary 
cultures of normal pancreas, but not in normal tissue (i.e. 
thymosin p3, cytokeratin 18, p-a&u, pyruvate kinase and 
mitochondrial genes); and (2) those corresponding to genes 
expressed at high levels in pancreas cancer cultures but not in 
normal pancreas tissue or cultured cells (i.e. tissue-type 
plasminogen activator and cathepsin H). The overexpression of 
these proteases in pancreas cancers suggests that they play a role 
in the aggressive biological behavior of this tumor. 
Key words: Pancreas cancer; Tissue-type plasminogen 
activator; Thymosin p4; Non-specific cross-reacting antigen; 
Subtractive hybridization 
1. Introduction 
Pancreas cancer is a highly aggressive tumor that currently 
represents the fourth cause of cancer death in the United 
States. The majority of tumors arise in the exocrine compo- 
nent and are classified as ‘ductal adenocarcinomas’ on the 
basis of their microscopic appearance [l]. Despite the fact 
that a number of molecular alterations have been reported 
which are associated with this tumor, including mutations in 
K-ras, ~53, and MTS-1 genes [2], there are few clues about the 
aggressive nature of its biological behavior. Epigenetic altera- 
tions also contribute to tumor progression. For example, 
overexpression of growth factor receptors and their ligands, 
such as c-metlhepatocyte growth factor, can lead to the acti- 
vation of autocrine and paracrine loops enhancing tumor cell 
motility, protease secretion, and invasiveness in vitro and in 
experimental models [3]. The biological relevance of these al- 
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terations is suggested by their association with a worse prog- 
nosis [4]. 
To get further insight into the molecular basis of pancreas 
cancer, we have sought to identify cDNAs which are over- 
expressed in pancreas cancer cells and may have a role in 
tumor progression. Several facts hamper the use of pancreas 
cancer tissue for these studies: (1) very few patients undergo 
tumor resection and it is difficult to obtain sufficient tissue to 
prepare a cDNA library, (2) unlike other tumors, surgical 
specimens from pancreas cancer generally contain a substan- 
tial proportion of non-neoplastic epithelial cells (i.e. ductal 
proliferation with the histological appearance of chronic ob- 
structive pancreatitis), inflammatory cells, and connective tis- 
sue. For example, in a recent study of pancreas cancer tissues, 
only 7/33 microdissected specimens contained 50% of tumor 
cells and could be subjected to allelotypic analysis [5]. Because 
of these difficulties, we have performed a subtraction between 
transcripts from SK-PC-l pancreas cancer cells and normal 
pancreas tissue. SK-PC-l cells were chosen because they were 
derived from a ductal adenocarcinoma and grow as a mono- 
layer of polarized cells, develop transepithelial resistance, and 
express molecular markers characteristic of ductal cells such 
as cytokeratins and mucins [6]. In addition, they contain dou- 
ble minutes and may harbor the amplification of genes im- 
portant for tumor progression [6]. 
We report here the isolation and identification of the cDNA 
clones obtained with this strategy as well as their expression in 
pancreas cancer cultures displaying a wide spectrum of phe- 
notypes and in normal exocrine pancreas cultures recently 
developed in our laboratory [7]. 
2. Materials and methods 
2.1. Cell culture 
Tumor cell lines were maintained in Dulbecco’s modified Eagle’s 
medium (gibco-BRL, Gaithersburg, MA) supplemented with 10% fe- 
tal bovineserum (Gibco-BRL) at 37°C in 5% CO* atmosphere. Pan- 
creas cancer cell lines IMIM-PC-l, IMIM-PC-2, SK-PC-l, and SK- 
PC-3 have been described recently [6]. Normal exocrine pancreas cul- 
tures displaying a ductal cell phenotype were established as described 
elsewhere [7]. 
2.2. RNA isolation 
Total RNA was isolated by acid guanidinium thiocyanate-phenol- 
chloroform extraction procedure [8]. Fresh normal pancreas tissue 
was obtained from organ donors and processed as described by Viii 
et al. in order to isolate the exocrine component [7]. Poly (A)+ RNA 
was prepared with the polyATract mRNA Isolation System (Prome- 
ga, Madison, WI) according to manufacturer’s instructions. Poly (A)+ 
RNA from fresh pancreatic tissue was prepared by affinity chroma- 
tography on oligo(dT)-cellulose columns. 
0014-5793/96/$12.00 0 1996 Federation of European Biochemical Societies. All rights reserved. 
PIISOO14-5793(96)00352-3 
R. Paciucci et al.IFEBS Letters 385 (1996) 72-76 
2.3. Subtractive hybridization 
cDNAs were synthesized on oligo(dT)-Dynabead particles (Dynal, 
Oslo, Norway) from SK-PC-l and normal pancreatic tissue poly (A)+ 
RNA. Target cDNA (SK-PC-l) labelling and subtractive hybridiza- 
tion were carried out as described by Rodriguez and Chandler, with 
minor modifications [9]. Briefly, target cDNA was used to synthesize 
radioactive fragments by random priming [lo] with Ready-Prime 
using [a-32P]dCTP (Amersham Iberica, Madrid, Spain); labelled frag- 
ments were recovered by elution and hybridized to an excess of nor- 
mal pancreas tissue cDNA (driver) immobilized onto Dynabeads for 
two consecutive rounds. Non-hybridized fragments were recovered 
and used as a probe to screen a SK-PC-l cDNA library. 
2.4. Construction and screening of the cDNA library 
Poly (A)+ RNA from 2 day post-confluent cultures of SK-PC-l 
cells was used to construct a library in LambdaZAP II according to 
the manufacturer’s instructions (Stratagene, La Jolla, CA). The li- 
brary was amplified before use. The subtracted probe was used to 
screen the SK-PC-l cDNA library according to standard methods 
[lo]. Positive clones were picked and subjected to three rounds of 
purification using the labelled subtracted probe. Isolated clones were 
excised in vivo and recovered as Bluescript plasmids. For dot hybri- 
dization, 10 ng of plasmid DNA from each isolated clone was spotted 
onto a nylon Hybond-N membrane (Amersham) and hybridized to 
labelled cDNA probes. 
2.5. Northern blot analysis 
Total RNA (15 lg) from cultured cells or tissues was electrophor- 
esed on 1% agarose-formaldehyde gels, transferred to nylon filters, 
and hybridized to [32P]dCTP labelled probes. Hybridizations were 
carried out overnight at 42”C, followed by washing at 60°C to final 
0.2 x SSC, and then autoradiography. The quality and quantity of the 
transferred RNA were assessed by ethidium bromide staining. 
2.6. DNA sequencing 
Sequencing of both strands of the isolated cDNA clones was per- 
formed by the dideoxynucleotide chain termination method either 
automatically, in an Applied Biosystem 373A DNA sequencer with 
Taq polymerase, or manually with Sequenase (United States Biochem- 
ical, Cleveland, OH) using universal primers (M13, T3, and T7) or 
internal specific primers. Sequences were compared against databases 
with the FASTDB and BLAST algorithms. 
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3. Results and discussion 
We used two rounds of hybridization of the transcribed 
cDNA derived from SK-PC-l cells with the cDNA derived 
from normal pancreatic tissue to obtain a probe enriched for 
genes overexpressed in the tumor cells. This probe was used to 
screen a SK-PC-l cDNA library and led to the isolation of 45 
clones, designated HPT for human pancreas tumor. Dot blot- 
ting analysis of several isolated clones (Fig. 1) confirmed that 
this method effectively enriched the probe for transcripts over- 
expressed in the tumor cells. All clones were purified and 300- 
400 nucleotide long sequences were obtained in order to de- 
termine identity to known genes. The results of such analysis, 
the homology to known genes and the expression pattern of 
each clone in cultured cells and tissue are summarized in Ta- 
ble 1. 
The pattern of expression of the isolated clones was exam- 
ined by Northern blotting with total RNA from SK-PC-l and 
normal pancreas tissue: all isolated cDNAs hybridized prefer- 
entially with RNA from the tumor cells. To examine the re- 
lationship between the levels of expression, cell differentiation, 
and the transformed phenotype, we used four pancreatic tu- 
mor cell lines selected on the basis of their differentiation 
properties. SK-PC-l and IMIM-PC-2 cells grow as a polar- 
ized monolayer, form domes, develop transepithelial resist- 
ance when cultured on permeable filters, and express markers 
Table 1. Identification and pattern of expression of cDNA clones 
obtained from screening the SK-PC-l library with ‘tumor enriched 
sequence’ probes 
Homology SK-PC-l Normal pancreas na 
Tissue Culture 
tPA +++b - _ 3 
NCA ++ _ _ 2 
Cathepsin H +++ f + 1 
HMGl ++ + + 1 
Pyruvate kinase + _ + 2 
cL-Tubulin +++ f ++ 2 
Mitochondrial RNAs +++ + ++ 5 
P-Actin ++ f +++ 3 
Ferritin H chain +++ ?r: +++ 3 
CK18 +++ + +++ 3 
TP4 +++ + +++ 20 
&n indicates the number of independent clones isolated homologous to 
the same gene. 
bThe level of expression for each clone was visually estimated from 
the intensity of the autoradiographic signals obtained by dot blot or 
Northern hybridization. 
typical of pancreatic ductal cells such as cytokeratin (CK) 7 
and the MUCl glycoprotein, indicating that they are well 
differentiated. In contrast, IMIM-PC-l and SK-PC-3 cells 
are not polarized, pile up, and express low or undetectable 
levels of CK7 and MUCl, indicating that they are less differ- 
entiated [6]. In addition, we examined transcript levels in 
RNA samples from primary cultures of normal exocrine pan- 
creas recently developed in our laboratory. These cells prolif- 
erate in vitro during 8-10 days and can be maintained for up 
to one month [7]. During the first days of culture, a pheno- 
typic switch takes place which involves loss of acinar charac- 
teristics and the acquisition of a phenotype that is undistin- 
guishable from that of normal pancreatic duct cells: growth as 
a polarized monolayer, expression of CK7, CK19, MUCl, 
and the cystic fibrosis transmembrane conductance regulator, 
and response to secretin [7]. 
A 
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Fig. 1. Expression of SK-PC-l-derived purified clones analyzed by 
dot blotting. cDNA clones were spotted onto replica nitrocellulose 
filters and hybridized to labeled SK-PC-l cDNA (A) and to labeled 
normal pancreas cDNA (B). The position of each clone is indicated 
in the bottom panel. 
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Fig. 2. Northern blotting analysis of the expression of selected 
clones in tumor cell lines and normal pancreas. Total RNA (15 pg) 
from the indicated tumor cell lines, two independent specimens of 
normal exocrine pancreas tissue (N.P.), and normal exocrine pan- 
creas epithelium cultured for various time periods, was transferred 
to nylon filters and hybridized to: (A) TP4, p-a&n, CK18, and pyr- 
uvate kinase (PK); (B) tPA, a 400 bp fragment from the 5’ region 
of the HPT-51 clone, cathepsin H, and NCA. A slower migrating 
band in the hybridization with the tPA probe results from cross-hy- 
bridization with 28s ribosomal RNA given by the high GC content 
of the probe used. Photographs of the 28s and 18s ribosomal RNA 
in ethidium bromide-stained gels are shown below the autoradio- 
graphs to normalize RNA deposits.The same filters were utilized to 
examine the expression of all clones shown in panels A and B. After 
each hybridization reaction, filters were stripped by incubation in 
boiling distilled water for two consecutive rounds, dried, and ex- 
posed for autoradiography for 48 h to evaluate for complete strip- 
ping before a new probe was added. 
t 
As summarized in Table 1, the clones isolated from the SK- 
PC-l library can be classified into two broad categories ac- 
cording to the levels of expression of the corresponding tran- 
scripts: (1) those expressed at high levels both in differentiated 
pancreas tumor cells and in normal primary cultures, but not 
in normal tissue, and (2) those expressed at high levels in 
differentiated pancreatic tumor cells but not in normal tissue 
or normal primary cultures. 
3.1. Clones corresponding to genes expressed at high levels in 
cultures of both pancreas cancer and normal pancreas 
epithelium 
This group includes genes whose products are involved in 
the regulation and formation of the cytoskeleton (TP4, p-ac- 
tin, CK18, a-tubulin) and in cell metabolism (pyruvate kinase, 
mitochondrial genes, ferritin heavy chain, and HMGl). With 
few exceptions, the levels of expression of these transcripts are 
low or undetectable in normal pancreas tissue (see Table 1 
and Fig. 2A). 
3.1.1. Genes encoding cytoskeleton-associated proteins. 
CK18 and p-actin transcripts are detected in all pancreas 
cancer cell lines, although higher levels are present in those 
with a more differentiated phenotype. Lower levels of expres- 
sion are observed in normal pancreas tissue and in normal 
exocrine pancreas cultures. In the latter, CK18 and p-actin 
mRNAs are induced around days 3-5 of culture, as shown 
in Fig. 2. It is possible that their expression is activated as a 
consequence of cell proliferation in vitro; however, the high 
levels of expression detected at day 15 (Fig. 2A and data not 
shown), when normal epithelial cells no longer proliferate, do 
not support this hypothesis. CK18 protein has been detected 
in all pancreas cancer tissues and cell lines examined [6,11] 
although there has been no systematic study aimed at quanti- 
tating RNA or protein levels, or at carefully assessing its 
relationship to cell differentiation. Despite the fact that tran- 
scriptional activation of CK18 has been reported in cells 
transformed by mutated Ha-ras [12], our results do not sup- 
port a relationship between CK18 levels and ras gene muta- 
tions in the four pancreas cancer cell lines examined since all 
of them harbor a mutated K-ras gene [13]. 
A remarkable finding was the very high proportion of the 
isolated cDNA clones (20/45) corresponding to TP4, possibly 
a reflection of the very high levels of expression detected, 
particularly in cultures of pancreas cancers and normal pan- 
creas epithelium (Table 1 and Fig. 2A). In the exponential 
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growth phase, the levels of TB4 detected in pancreas cancer 
cells were much higher than in other lines studied, i.e. HT-29 
colon cancer and SK-MEL-23 melanoma (data not shown). 
Furthermore, high levels were also detected in normal pan- 
creas epithelium at days 10-15 of culture. Thus, although TB4 
expression has been associated with cell proliferation in lym- 
phoid cells [14], our data do not support a straightforward 
relationship between the increased expression of this tran- 
script and cell proliferation. The precise significance of this 
overexpression in tumor cells is unknown. Beta-thymosins are 
the major actin-binding proteins in cells [15] and a role in 
differentiation and metastasis has been proposed in a variety 
of cellular systems. In astrocytes and microglia from rat cer- 
ebellum, TB4 and TBlO are selectively regulated during cell 
differentiation and their tissue expression pattern is main- 
tained in cultured cells [16]. TBlO has also been isolated by 
subtractive cloning from metastatic melanoma cells and its 
participation in tumor metastasis through regulation of actin 
polymerization has been proposed in this tumor system [17]. 
3.1.2. Genes whose products are involved in cell metabo- 
lism. The expression of Ml- and MZ-type pyruvate kinase, 
ferritin heavy chain, and mitochondrial tRNAs is high both in 
pancreatic tumor cells and in normal cultures (Table 1 and 
Fig. 2A). Recent reports have implicated both pyruvate kinase 
and mitochondrial genes in cancer development. Increased 
expression and genomic insertion of mitochondrial genes 
have been described in association with cancer [18]. High ex- 
pression of these genes has also been described in trophoblasts 
from normal placenta, a tissue defined as pseudomalignant, 
and it has been proposed that increased expression of these 
genes may be an early event in cancer development [19]. The 
L-pyruvate kinase gene is slightly active in the normal and 
neoplastic endocrine pancreas but it is not transcribed in the 
normal exocrine pancreas in vivo, despite the fact that its 
promoter remains in a permissive state for re-expression 
[20]. Our results show that both normal cultures and cancer 
cells express pyruvate kinase and mitochondrial genes at ele- 
vated levels when compared with the normal tissue (Table 1 
and Fig. 2A), suggesting that such overexpression may not be 
directly related to the neoplastic state. Instead, it seems to 
associate better with the ductal phenotype of pancreas cancer 
and the acinar-to-ductal phenotypical switch accompanying 
the culture of normal pancreas epithelium. 
3.2. Clones corresponding to genes expressed at high levels 
exclusively in tumor cells 
This group comprises cDNAs encoding tissue-type plasmin- 
ogen activator (tPA), cathepsin H, and non-specific cross-re- 
acting antigen (NCA). Fig. 2B shows that tPA transcripts are 
present at high levels in SK-PC-l cells, at lower levels in 
IMIM-PC-2 cells, and are undetectable in less differentiated 
pancreas cancer cells, in normal pancreas tissue and normal 
exocrine pancreas cultures. High levels of tPA, similar to 
those of SK-PC-l cells, have been detected in MZPC-2 and 
MZPC-3 (data not shown), two cell lines which also display a 
differentiated ductal phenotype.The relevance of the findings 
reported above is strengthened by the fact that tPA overex- 
pression at the RNA and protein levels occurs both in pan- 
creas cancer cells and tissues (R.P., unpublished results). 
These results indicate that overexpression of tPA is associated 
with the neoplastic phenotype rather than with the differentia- 
tion program activated in cells derived from the exocrine pan- 
creas. Secreted proteases have a prominent role in the degra- 
dation of extracellular matrix components during tissue 
remodelling and tumor invasion [21]. Overexpression of the 
plasminogen activator urokinase, together with its receptor, 
has been associated with invasive tumor cells in many types 
of cancers [22], and inhibition of receptor expression by anti- 
sense oligonucleotides results in a reduction of invasiveness 
[23,24]. In addition, uPA levels appear to be a prognostic 
factor in several types of cancer [22]. Fewer studies have ana- 
lyzed the expression of tPA in tumors and its possible role in 
cancer progression, possibly because this protease is thought 
to participate in plasmin activation mainly in the vascular 
compartment [25]. In this regard, tPA expression has been 
reported in ovarian cancer cultures but not in normal ovary 
epithelium [26]. 
High levels of expression of cathepsin H gene are also de- 
tected in pancreas cancer cells showing a well differentiated 
phenotype, but not in less differentiated cancer cells nor in 
normal cultures (Fig. 2B). Little information is available re- 
garding the expression of the thiol proteases in normal pan- 
creas and pancreas cancer. Yamaguchi et al. have reported the 
secretion of cathepsin L by HPC-YP pancreas cancer cells and 
have suggested that a dimer of the mature form and the 
proenzyme is formed. However, no comparison with normal 
pancreas was made [27]. Tumor cells often secrete high levels 
of lysosomal enzymes such as cathepsins, indicating a defec- 
tive intracellular processing. Upon secretion, these proteases 
may also contribute to the degradation of pericellular matrix 
and to tumor cell invasiveness [28]. In the context of these 
observations, our results indicate that overexpression of tPA 
and cathepsin H, and possibly other proteases that have been 
identified recently [29], is associated with cancer of the exo- 
crine pancreas. 
The expression pattern of NCA was very similar to that of 
tPA: high levels in well differentiated cell lines, but not in 
poorly differentiated cell lines, and undetectable levels in nor- 
mal pancreas cultures (Fig. 2 and data not shown), indicating 
a relationship to the neoplastic phenotype rather than to cell 
differentiation. In a recent report, a mouse monoclonal anti- 
body detecting NCA-related molecules showed strong reactiv- 
ity with pancreas cancers and cDNA clones corresponding to 
the NCA gene have been isolated from a cDNA library de- 
rived from GER pancreas cancer cell line [30], supporting our 
own findings. NCA belongs to the carcinoembryonic antigen 
(CEA) family together with CEA, biliary glycoprotein, the 
CEA-gene family members, and pregnancy-specific glycopro- 
tein. CEA and biliary glycoprotein mediate homophyllic inter- 
actions but the function of NCA and the other members of 
the CEA family is currently unknown. Antibodies have been 
extensively used to examine the expression of molecules be- 
longing to the CEA family in normal and tumor tissues but 
the interpretation of these studies is hampered because of the 
immunological relatedness of CEA and NCA. Recent obser- 
vations utilizing monoclonal antibodies that distinguish be- 
tween the two proteins suggest that NCA is more widely over- 
expressed in human tumors than CEA [31,32]. 
4. Conclusions 
Our strategy has led to the isolation of cDNAs correspond- 
ing to transcripts overexpressed in pancreas cancer. Those 
related to proteins involved in the structure and regulation 
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of the cytoskeleton and in cell metabolism appear to associate 
with the ductal differentiation observed in most tumors of the 
exocrine pancreas. Others, such as tPA, cathepsin H, and 
NCA, seem to be more directly related to the neoplastic phe- 
notype. Because Southern blotting failed to reveal any evi- 
dence for amplification of the genes encoding tPA or NCA 
(data not shown), other mechanisms are likely to account for 
the high transcript levels detected and more work is necessary 
in this area. 
The results of this study provide new clues to the study of 
cancer of the exocrine pancreas. Detection of the products of 
genes that are overexpressed may provide important informa- 
tion and be useful in monitoring the disease. 
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